PowerCore combining structure and batteries for increased energy toweight ratio

Much of the mass of a battery is comprised of nonreactive materials. In an NiH₂ battery, this includes the pressure vessel and 50% of the positive electrode. PowerCore reconfigures the battery materials to serve as a structural sandwich panel. The effective specific energy of the new device can exceed 100 Wh/kg. PowerCore is intended to handle power demands of low Earth orbiting communications satellites such as IRIDIUM. This paper describes the concept and development progress     

Communicating across the solar system

The technological advances of the Space Age have enabled us to project our senses through complex instruments to the edge of the Solar System and beyond. The link back to Earth by the communication channel has provided us with a wealth of information. The vast improvement in communication capability, by a factor of 10¹⁸, from the launching of the first earth satellites to the capacity of the Voyager telecommunications link across the Solar System, is symbolic of both our technical prowess and our cultural development. The combination of data rate and extreme distance at the Voyager 2 encounters with Uranus and Neptune in 1986 and 1989 will require the ground network to perform an engineering feat of unequalled magnitude. This paper describes the engineering challenge of communicating with spacecraft at the limits of the Solar System and the engineering responses to that challenge.     

Space motion sickness medications: interference with biomedical parameters

The possibility that drugs administered to Skylab 3 (SL-3) and 4 (SL-4) crewmen for space motion sickness may have interfered with their biomedical evaluation in space was investigated. Healthy volunteers received combinations of Scopolamine/Dexedrine for four days in regimens similar to those used in these missions. Urine samples, heart rate, body temperature, mood and performance were analyzed for drug-related changes. Twenty-four hour urine samples were analyzed by the same procedures as those used to analyze the flight samples. Hormone concentrations determined included cortisol, epinephrine, norepinephrine, aldosterone and antidiuretic hormone (ADH). In addition, volume, specific gravity, osmolarity, sodium (Na), potassium (K), calcium (Ca), magnesium (Mg), chloride (Cl), inorganic phosphate, uric acid and creatinine were measured. Performance was not affected by the Scopolamine/Dexedrine. The drug combination increased daily mean heart rate (HR) significantly in all the subjects and daily mean rectal temperature (RT) in some of the subjects. A 2-4 hr phase shift in the HR circadian rhythm was also observed which indicates that internal circadian synchrony was disturbed by the drugs. Psychological and subjective evaluation indicated that the subjects could usually identify which days they were given the drugs by an increase in tension and anxiety, decreased patience, restlessness, decreased appetite, difficulty in sleeping and feelings of increased heart rate and body temperature. Urinary electrolytes were not changed significantly by the drug, but marked and significant changes occurred in urine volume and hormone excretion patterns. Scopolamine/Dexedrine caused consistent elevations in urinary cortisol and epinephrine and a transient elevation in ADH. Norepinephrine excretion was decreased, but there was no significant change in aldosterone excretion or in 24 hr urine volume. A comparison of these findings with the first four days of inflight data from the SL-3 and SL-4 missions leads to the conclusion that the dramatic increases in aldosterone excretion during the first three days of spaceflight probably can be directly attributed to weightlessness, whereas the antimotion sickness medication could have substantially contributed to the early increased excretion of epinephrine and cortisol during these missions.